TEL
50
-2
GOOGL
37
-5
VIX
71
5
BK
54
-4
ADM
36
2
BAC
44
-3
FOXA
45
-5
HOG
39
3
COP
30
3
HUM
34
-2
NSC
36
-6
L
52
-3
AMAT
38
-4
DTE
34
-2
MMM
33
-5
NFLX
64
-4
MS
55
-2
HPE
35
12
IFF
33
-5
NVDA
42
-10
TEL
50
-2
GOOGL
37
-5
VIX
71
5
BK
54
-4
ADM
36
2
BAC
44
-3
FOXA
45
-5
HOG
39
3
COP
30
3
HUM
34
-2
NSC
36
-6
L
52
-3
AMAT
38
-4
DTE
34
-2
MMM
33
-5
NFLX
64
-4
MS
55
-2
HPE
35
12
IFF
33
-5
NVDA
42
-10
Financhill
Back

Reshape Lifesciences 10K Form

Sell
14

RSLS
Reshape Lifesciences

Last Price:
$0.31
Seasonality Move:
-20.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RSLS News And Ratings

See the #1 stock for the next 7 days that we like better than RSLS

RSLS Financial Statistics

Sales & Book Value

Annual Sales: $8M
Cash Flow: $-311K
Price / Cash Flow: 0
Annual Sales: $2.11
Price / Book: 0.18

Profitability

EPS (TTM): -16.00850
Net Income (TTM): $-7.1M
Gross Margin: $5.1M
Return on Equity: -187.93%
Return on Assets: -91.24%

Reshape Lifesciences Earnings Forecast

Key Reshape Lifesciences Financial Ratios

  • The Gross Profit Margin over the past 17 years for RSLS is 63.17%.
  • The Selling, General & Administrative Expenses for RSLS have been equal to 123.93% of Gross Profit Margin.
  • The Research & Development expenses have been 22.52% of Revenue.
  • The Net Earning history of RSLS is -89.06% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 12 years.

Reshape Lifesciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: RSLS
CUSIP: 761123
Website: reshapelifesciences.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.33
Quick Ratio: 0.52

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RSLS Technical Analysis vs Fundamental Analysis

Sell
14
Reshape Lifesciences (RSLS) is a Sell

Is Reshape Lifesciences a Buy or a Sell?